{
    "name": "clindamycin vaginal",
    "comment": "Rx",
    "other_names": [
        "Clindesse Vaginal Cream",
        "Cleocin Vaginal Cream",
        "Cleocin Vaginal Ovules",
        "Xaciato"
    ],
    "classes": [
        "Vaginal Preparations",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/clindesse-vaginal-cream-cleocin-vaginal-cream-clindamycin-vaginal-4000260",
    "pregnancy": {
        "common": [
            "Other clindamycin vaginal products have been used to treat pregnant females during the second and third trimester",
            "Not studied in pregnant females"
        ],
        "specific": [
            {
                "type": "Clindesse vaginal cream",
                "description": [
                    "Use during pregnancy only if clearly needed",
                    "No adequate and well-controlled studies in pregnant females have been conducted"
                ]
            },
            {
                "type": "Cleocin vaginal cream or suppositories",
                "description": [
                    "There are no adequate and well-controlled studies in pregnant females during first trimester; use only if clearly needed and benefits outweigh risks",
                    "In clinical trials with pregnant women, systemic administration of clindamycin during the second and third trimesters, has not been associated with an increased frequency of congenital abnormalities",
                    "Studied in pregnant females during the second trimester; in those treated for 7 days, abnormal labor was reported in 1.1% of patients who received clindamycin vaginal cream compared with 0.5% of patients who received placebo"
                ]
            },
            {
                "type": "Xaciato",
                "description": [
                    "Based on the low systemic absorption following the intravaginal route of administration in nonpregnant females, maternal use is not likely to result in significant fetal exposure to the "
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Not compatible with and may weaken polyurethane condoms; therefore, use of polyurethane condoms is not recommended during and for 7 days following treatment ",
                    "Advise patients to use latex or polyisoprene condoms for contraception during and for 7 days following treatment"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown if excreted in human breast milk following use of vaginally administered clindamycin phosphate; detected in human milk after PO or IV administration",
            "Clindamycin has the potential to cause adverse effects on breastfed infantsâ€™ gastrointestinal flora"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to clindamycin or other lincosamides",
                "Regional enteritis, ulcerative colitis, or history of ",
                "Clostridium difficile",
                "-associated diarrhea",
                "Clostridium difficile",
                "-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin, and may range in severity from mild diarrhea to fatal colitis; if suspected or confirmed, ongoing antibiotic use not directed against ",
                "C difficile",
                " may need to be discontinued; initiate fluid and electrolyte management, protein supplementation, antibiotic treatment of ",
                "C difficile",
                "Do not use barrier contraceptives (eg, condoms, diaphragms) not recommended concurrently or for 5 days following treatment with clindamycin vaginal creams or suppositories; the creams contain mineral oil and the suppositories contain an oleaginous base that may weaken latex or rubber products"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Fungal vaginosis",
            "percent": "14"
        },
        {
            "name": "Cleocin vaginal cream H",
            "percent": "4"
        },
        {
            "name": "Vaginal moniliasis",
            "percent": "7.1-13.3"
        },
        {
            "name": "Vulvovaginal candidiasis",
            "percent": "17"
        },
        {
            "name": "Headache",
            "percent": "7"
        },
        {
            "name": "Back pain",
            "percent": "5"
        },
        {
            "name": "Constipation",
            "percent": "2"
        },
        {
            "name": "Urinary tract infection",
            "percent": "2"
        },
        {
            "name": "Vulvovaginitis",
            "percent": "4.4-6"
        },
        {
            "name": "Vulvovaginal disorder",
            "percent": "3.2-7.1"
        },
        {
            "name": "Trichomonal vaginitis",
            "percent": "1.3"
        },
        {
            "name": "Moniliasis",
            "percent": "0.2-1.3"
        },
        {
            "name": "body",
            "percent": "1.1"
        },
        {
            "name": "Pruritus",
            "percent": "3.4"
        },
        {
            "name": "nonapplication site",
            "percent": "1.9"
        },
        {
            "name": "Vulvovaginal disorder",
            "percent": "1.5"
        },
        {
            "name": "Vaginal pain",
            "percent": "1"
        },
        {
            "name": "Vaginal moniliasis",
            "percent": "17"
        },
        {
            "name": "Fungal infection",
            "percent": null
        },
        {
            "name": "Vulvovaginal candidiasis",
            "percent": null
        }
    ]
}